Skip to main content
. 2021 Jun 17;118(7):1713–1727. doi: 10.1093/cvr/cvab208

Figure 1.

Figure 1

Senescence markers in primary human and mouse VSMCs undergoing senescence. (A) % EdU+ in cultured human VSMCs (Control), after 24h treatment with 500 nM doxorubicin (Dox 1d), after an additional 21 days recovery in control conditions (control 21d) or after doxorubicin (Dox 1d+ 21d), or at replicative senescence (RS). (B–D) mRNA levels of Lamin B1, p16, and p21 in cell populations described in (A) relative to control (1d) cells. (E) Western blot for Lamin B1, p16, p21, and p53 for cells treated in (A). n = 6–8 human VSMC isolates. (F and G) EdU+ % (F) or SAβG+ % (G) of mouse p16-3MR VSMCs treated increasing concentrations of Doxorubicin for 1 day followed by 7 days recovery vs. vehicle control. (I–K) qPCR for Lamin B1, IL6, p16, or p21 mRNA expression for cells treated in (F). (L) Western blot of mouse cells as treated in (F) for Lamin B1, p16, or p21. n = 3–8 mouse VSMC isolates. Data are means (SD), one-way ANOVA with correction for multiple comparisons (A) or unpaired Student’s t-test vs. Control 1d (B–D) or vs. Vehicle (Dox 0 nM) (F–K).